TORONTO, Feb. 25, 2016 /CNW/ - Teva Canada Limited, a
subsidiary of Teva Pharmaceutical Industries Ltd., announced that
Health Canada has approved its application for the generic version
of PrTobi®. This respiratory antibiotic is indicated for
the management of cystic fibrosis patients with chronic pulmonary
Pseudomonas aeruginosa (P. aeruginosa)
infections.
PrTobi® had annual sales of approximately
$9.5 million in Canada, based on IMS Brogan sales data as of
November 2015.
PrTeva-Tobramycin Inhalation Solution is
available immediately in pharmacies across Canada. Teva Canada is the sole generic supplier of this
treatment in Canada.
"Cystic fibrosis is a devastating genetic disorder where nearly
half of the 4,000 affected Canadians will become infected with
harmful bacterial in their lungs caused by Pseudomonas
aeruginosa," said Doug
Sommerville, General Manager, Teva Canada Limited. "As the
sole generic supplier of Tobramycin Inhalation Solution we
endeavour to play an active role in supplying patients with a lower
cost option to help facilitate the medical treatment of this
infection."
Cystic fibrosis is a multi-system disease affecting mainly the
lungs and digestive system of young Canadians. According to
the Public Health Agency of Canada, 30 to 40 per cent of those with
cystic fibrosis will acquire a chronic pseudomonal
infection.i
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare
solutions for 50 years, with nearly 200,000ii
prescriptions filled with our products every day. Originally
Novopharm Limited, Teva Canada
specializes in the development, production and marketing of
high-quality generic prescription pharmaceuticals and through our
branded division, Teva Canada Innovation, focuses on a diverse line
of innovative products in a variety of therapeutic areas.
Teva Canada employs more than 1,300
individuals, markets more than 400iii products in
Canada and is a subsidiary of Teva
Pharmaceutical Industries Ltd., the world's largest generic drug
maker. For more information, visit:
www.tevacanada.com or
www.tevamakesmedicines.ca
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every
day. Headquartered in Israel, Teva
is the world's largest generic medicines producer, leveraging its
portfolio of more than 1,000 molecules to produce a wide range of
generic products in nearly every therapeutic area. In specialty
medicines, Teva has a world-leading position in innovative
treatments for disorders of the central nervous system, including
pain, as well as a strong portfolio of respiratory products. Teva
integrates its generics and specialty capabilities in its global
research and development division to create new ways of addressing
unmet patient needs by combining drug development capabilities with
devices, services and technologies. Teva's net revenues in 2015
amounted to $19.7 billion. For more
information, visit www.tevapharm.com.
i Public Health Agency of Canada. Pseudomonas
Spp.
http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/pseudomonas-spp-eng.php.
Accessed February 2016.
ii IMS Compuscript TRx MAT December 2015
iii IMS CD&H MAT December
2015
SOURCE Teva Canada Limited